Cargando…

Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report

BACKGROUND: Cancers of the Vater ampulla (ampullary cancers, ACs) account for less than 1% of all gastrointestinal tumors. ACs are usually diagnosed at advanced stage, with poor prognosis and limited therapeutic options. BRCA2 mutations are identified in up to 14% of ACs and, differently from other...

Descripción completa

Detalles Bibliográficos
Autores principales: Mauri, Gianluca, Gori, Viviana, Patelli, Giorgio, Roazzi, Laura, Rizzetto, Francesco, De Carlis, Luciano, Mariani, Anna, Cavallari, Ugo, Prada, Elisabetta, Cipani, Tiziana, Aquilano, Maria Costanza, Bonoldi, Emanuela, Vanzulli, Angelo, Siena, Salvatore, Sartore-Bianchi, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064505/
https://www.ncbi.nlm.nih.gov/pubmed/36998040
http://dx.doi.org/10.1186/s12957-023-02976-0
_version_ 1785017906438864896
author Mauri, Gianluca
Gori, Viviana
Patelli, Giorgio
Roazzi, Laura
Rizzetto, Francesco
De Carlis, Luciano
Mariani, Anna
Cavallari, Ugo
Prada, Elisabetta
Cipani, Tiziana
Aquilano, Maria Costanza
Bonoldi, Emanuela
Vanzulli, Angelo
Siena, Salvatore
Sartore-Bianchi, Andrea
author_facet Mauri, Gianluca
Gori, Viviana
Patelli, Giorgio
Roazzi, Laura
Rizzetto, Francesco
De Carlis, Luciano
Mariani, Anna
Cavallari, Ugo
Prada, Elisabetta
Cipani, Tiziana
Aquilano, Maria Costanza
Bonoldi, Emanuela
Vanzulli, Angelo
Siena, Salvatore
Sartore-Bianchi, Andrea
author_sort Mauri, Gianluca
collection PubMed
description BACKGROUND: Cancers of the Vater ampulla (ampullary cancers, ACs) account for less than 1% of all gastrointestinal tumors. ACs are usually diagnosed at advanced stage, with poor prognosis and limited therapeutic options. BRCA2 mutations are identified in up to 14% of ACs and, differently from other tumor types, therapeutic implications remain to be defined. Here, we report a clinical case of a metastatic AC patient in which the identification of a BRCA2 germline mutation drove a personalized multimodal approach with curative-intent. CASE PRESENTATION: A 42-year-old woman diagnosed with stage IV BRCA2 germline mutant AC underwent platinum-based first line treatment achieving major tumor response but also life-threatening toxicity. Based on this, as well as on molecular findings and expected low impact of available systemic treatment options, the patient underwent radical complete surgical resection of both primary tumor and metastatic lesions. Following an isolated retroperitoneal nodal recurrence, given the expected enhanced sensitivity to radiotherapy in BRCA2 mutant cancers, the patient underwent imaging-guided radiotherapy leading to long-lasting complete tumor remission. After more than 2 years, the disease remains radiologically and biochemically undetectable. The patient accessed a dedicated screening program for BRCA2 germline mutation carriers and underwent prophylactic bilateral oophorectomy. CONCLUSIONS: Even considering the intrinsic limitations of a single clinical report, we suggest that the finding of BRCA germline mutations in ACs should be taken into consideration, together with other clinical variables, given their potential association with remarkable response to cytotoxic chemotherapy that might be burdened with enhanced toxicity. Accordingly, BRCA1/2 mutations might offer the opportunity of personalizing treatment beyond PARP inhibitors up to the choice of a multimodal approach with curative-intent.
format Online
Article
Text
id pubmed-10064505
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100645052023-04-01 Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report Mauri, Gianluca Gori, Viviana Patelli, Giorgio Roazzi, Laura Rizzetto, Francesco De Carlis, Luciano Mariani, Anna Cavallari, Ugo Prada, Elisabetta Cipani, Tiziana Aquilano, Maria Costanza Bonoldi, Emanuela Vanzulli, Angelo Siena, Salvatore Sartore-Bianchi, Andrea World J Surg Oncol Case Report BACKGROUND: Cancers of the Vater ampulla (ampullary cancers, ACs) account for less than 1% of all gastrointestinal tumors. ACs are usually diagnosed at advanced stage, with poor prognosis and limited therapeutic options. BRCA2 mutations are identified in up to 14% of ACs and, differently from other tumor types, therapeutic implications remain to be defined. Here, we report a clinical case of a metastatic AC patient in which the identification of a BRCA2 germline mutation drove a personalized multimodal approach with curative-intent. CASE PRESENTATION: A 42-year-old woman diagnosed with stage IV BRCA2 germline mutant AC underwent platinum-based first line treatment achieving major tumor response but also life-threatening toxicity. Based on this, as well as on molecular findings and expected low impact of available systemic treatment options, the patient underwent radical complete surgical resection of both primary tumor and metastatic lesions. Following an isolated retroperitoneal nodal recurrence, given the expected enhanced sensitivity to radiotherapy in BRCA2 mutant cancers, the patient underwent imaging-guided radiotherapy leading to long-lasting complete tumor remission. After more than 2 years, the disease remains radiologically and biochemically undetectable. The patient accessed a dedicated screening program for BRCA2 germline mutation carriers and underwent prophylactic bilateral oophorectomy. CONCLUSIONS: Even considering the intrinsic limitations of a single clinical report, we suggest that the finding of BRCA germline mutations in ACs should be taken into consideration, together with other clinical variables, given their potential association with remarkable response to cytotoxic chemotherapy that might be burdened with enhanced toxicity. Accordingly, BRCA1/2 mutations might offer the opportunity of personalizing treatment beyond PARP inhibitors up to the choice of a multimodal approach with curative-intent. BioMed Central 2023-03-31 /pmc/articles/PMC10064505/ /pubmed/36998040 http://dx.doi.org/10.1186/s12957-023-02976-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Mauri, Gianluca
Gori, Viviana
Patelli, Giorgio
Roazzi, Laura
Rizzetto, Francesco
De Carlis, Luciano
Mariani, Anna
Cavallari, Ugo
Prada, Elisabetta
Cipani, Tiziana
Aquilano, Maria Costanza
Bonoldi, Emanuela
Vanzulli, Angelo
Siena, Salvatore
Sartore-Bianchi, Andrea
Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report
title Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report
title_full Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report
title_fullStr Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report
title_full_unstemmed Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report
title_short Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report
title_sort multimodal treatment with curative intent in a germline brca2 mutant metastatic ampullary adenocarcinoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064505/
https://www.ncbi.nlm.nih.gov/pubmed/36998040
http://dx.doi.org/10.1186/s12957-023-02976-0
work_keys_str_mv AT maurigianluca multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport
AT goriviviana multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport
AT patelligiorgio multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport
AT roazzilaura multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport
AT rizzettofrancesco multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport
AT decarlisluciano multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport
AT marianianna multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport
AT cavallariugo multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport
AT pradaelisabetta multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport
AT cipanitiziana multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport
AT aquilanomariacostanza multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport
AT bonoldiemanuela multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport
AT vanzulliangelo multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport
AT sienasalvatore multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport
AT sartorebianchiandrea multimodaltreatmentwithcurativeintentinagermlinebrca2mutantmetastaticampullaryadenocarcinomaacasereport